Get in touch

The global market was valued at ~$22 billion in 2022 and is projected to reach $47 billion by 2034 (6–7% CAGR) Market Insights.

Electrome is a next-gen biotech company with a lead product poised for launch, revenue in year one, and a scalable platform to lead the emerging bioelectric category. See our Investor Deck.

Decades of peer-reviewed research demonstrate that PEMF modulates voltage-gated ion channels, TRPA1/TRPV1 receptors, and calcium signaling—accelerating healing, reducing pain, and impairing bacterial growth. See Science.

Yes. Peer-reviewed evidence supports PEMF for pain, wound healing, osteoarthritis, fracture repair, infection control, neuroplasticity, and adjunctive oncology. Our Research Library provides detailed studies.

PEMF is non-systemic, often drug-sparing, and typically free of systemic side effects. Many studies show it can reduce medication requirements while improving healing outcomes. Read more in Science.

Yes. Clinical trials and real-world data (e.g., Houston VA 27.12 MHz PEMF protocols) show reduced opioid use, faster recovery, and improved quality of life. Watch case studies in Clinical Proof.

A full-stack system that links wearable PEMF tACS/pemf devices with biosensors, AI-driven dosing algorithms, and the Electrome Knowledge Graph. Details in Platform Overview.

An AI-enhanced library mapping signal patterns to biological outcomes, integrating molecular data, peer-reviewed studies, and clinical results. Discover more via Knowledge Graph.

Our proprietary engine uses machine learning to predict and optimize signal bioefficacy across conditions—prioritizing new therapies in silico before clinical deployment. Explore at Discovery Engine.

Real-time feedback—heart rate variability, tissue impedance, sleep cycles—guides adaptive waveform modulation via secure firmware and cloud analytics. See Therapy Personalization.

Our first-generation PEMF sleeve is ready for launch. Additional modules for neuro, oncology, and infection applications are in development. View Device Roadmap.

Partnerships & Collaboration

Absolutely. We’re looking for co-development and signal-drug combo strategies to accelerate efficacy and reduce dosages. Learn more under Pharma Partnerships.

Yes—we are onboarding pilot sites across multi-specialty surgery, wound care, pain management, and oncology. See Partner with Us.

Yes—our lead product follows an FDA 510(k)-predicated route using 27.12 MHz. Learn about our regulatory strategy in Regulatory.

Investors & Funding

Yes—we are in an active investment round targeting both institutional and strategic investors. Download our Investor Deck.

With projected penetration into pain and wound care markets alone (~$50B total market size) and platform scalability across indications, Electrome projects multi-hundred-million revenue by Year 3. High-level forecasts in Investor Insights.

Write us at press@electrotx.com. Our leadership is available for conferences, media, and expert commentary.

For pharma, clinical, or academic collaboration inquiries, email partner@electrotx.com.

For investment discussions or follow-on rounds, please reach out at invest@electrotx.com.

If you’d like to reshape answers for clinical audiences, media sections, or investor FAQs, I’m happy to assist!